<DOC>
	<DOCNO>NCT02224664</DOCNO>
	<brief_summary>This study open label , dose escalation study investigate safety , tolerability , pharmacokinetics pharmacodynamics repeat daily quaque die ( QD ) dose give 21 day ( Day 3 Day 23 ) sequential cohort subject Parkinson 's disease . Each cohort 2 study period . For cohort , subject enter Period 1 meet criterion , approximately 12 subject enrol Period 2 dose PF 06649751 . Based result observe previous study , Cohorts 1 2 conduct . Cohorts 3 - 6 test dos uptitrated 5 mg , 15 mg 25 mg QD . Doses may modify base emerge safety , tolerability PK data , maximum daily dose give cohort PK prediction steady state anticipate toxicokinetic limit . An option titration previous dose level available investigator consider AE intolerable . Following titration , single titration next dose level may attempt subject remain symptom free least 48 hr . Safety , tolerability PK data Cohort 3 review prior initiate dose Cohorts 4 5 . Available safety , tolerability PK data Day 24 least 5 subject Cohorts 4 review prior initiate dose Cohort 6 .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics PF-06649751 Parkinson ` Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Clinical diagnosis idiopathic Parkinson 's Disease least 2 3 cardinal characteristic ( tremor , rigidity , bradykinesia ) MiniMental State Examination ( MMSE ) â‰¥ 25 Hoehn &amp; Yahr Stage IIII inclusive Documented history end LDopa wear OFF Cohort 5 : History dyskinesia follow LDopa dose Score least 2 Part IV , item 4.2 ( functional impact dyskinesia ) MDSUPDRS Atypical/secondary parkinsonism History surgical intervention Parkinson 's Disease Dementia/cognitive impairment interfere study assessment</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>